Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

425 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Feasibility of reduced port surgery applying Higuchi's transverse incision.
Ueda K, Nagayoshi Y, Kawabata A, Kuroda T, Iida Y, Saitou M, Yanaihara N, Sugimoto K, Sakamoto M, Okamoto A. Ueda K, et al. Among authors: kawabata a. Gynecol Minim Invasive Ther. 2017 Jan-Mar;6(1):12-16. doi: 10.1016/j.gmit.2016.05.003. Epub 2016 Jun 15. Gynecol Minim Invasive Ther. 2017. PMID: 30254862 Free PMC article.
Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.
Jang JYA, Yanaihara N, Pujade-Lauraine E, Mikami Y, Oda K, Bookman M, Ledermann J, Shimada M, Kiyokawa T, Kim BG, Matsumura N, Kaku T, Kuroda T, Nagayoshi Y, Kawabata A, Iida Y, Kim JW, Quinn M, Okamoto A. Jang JYA, et al. Among authors: kawabata a. J Gynecol Oncol. 2017 Jul;28(4):e54. doi: 10.3802/jgo.2017.28.e54. J Gynecol Oncol. 2017. PMID: 28541641 Free PMC article. Review.
PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma.
Morikawa A, Hayashi T, Shimizu N, Kobayashi M, Taniue K, Takahashi A, Tachibana K, Saito M, Kawabata A, Iida Y, Ueda K, Saito M, Yanaihara N, Tanabe H, Yamada K, Takano H, Nureki O, Okamoto A, Akiyama T. Morikawa A, et al. Among authors: kawabata a. Oncotarget. 2018 Feb 22;9(20):15266-15274. doi: 10.18632/oncotarget.24555. eCollection 2018 Mar 16. Oncotarget. 2018. PMID: 29632642 Free PMC article.
Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.
Takenaka M, Köbel M, Garsed DW, Fereday S, Pandey A, Etemadmoghadam D, Hendley J, Kawabata A, Noguchi D, Yanaihara N, Takahashi H, Kiyokawa T, Ikegami M, Takano H, Isonishi S, Ochiai K, Traficante N, Gadipally S, Semple T, Vassiliadis D, Amarasinghe K, Li J, Mir Arnau G, Okamoto A, Friedlander M, Bowtell DDL; Australian Ovarian Cancer Study Group. Takenaka M, et al. Among authors: kawabata a. Clin Cancer Res. 2019 Jul 1;25(13):3962-3973. doi: 10.1158/1078-0432.CCR-18-3691. Epub 2019 Apr 9. Clin Cancer Res. 2019. PMID: 30967419
Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma.
Seki T, Yanaihara N, Shapiro JS, Saito M, Tabata J, Yokomizo R, Noguchi D, Kuroda T, Kawabata A, Suzuki J, Takahashi K, Matsuzawa H, Miyake M, Takenaka M, Iida Y, Yanagida S, Okamoto A. Seki T, et al. Among authors: kawabata a. Sci Rep. 2021 Apr 8;11(1):7689. doi: 10.1038/s41598-021-86913-9. Sci Rep. 2021. PMID: 33833265 Free PMC article.
425 results